Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59,145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma.
Liu H, Zhao Q, Tan L, Wu X, Huang R, Zuo Y, Chen L, Yang J, Zhang ZX, Ruan W, Wu J, He F, Fang Y, Mao F, Zhang P, Zhang X, Yin P, Yan Z, Xu W, Lu H, Li Q, Liang M, Jia Y, Chen C, Xu S, Shi Y, Ping YF, Duan GJ, Yao XH, Han Z, Pang T, Cui Y, Zhang X, Zhu B, Qi C, Wang Y, Lv SQ, Bian XW, Liu X. Liu H, et al. Among authors: wu x, wu j. Cancer Cell. 2023 Apr 10;41(4):693-710.e8. doi: 10.1016/j.ccell.2023.03.004. Epub 2023 Mar 23. Cancer Cell. 2023. PMID: 36963400 Free article.
Corrigendum to "Norisoboldine ameliorates collagen-induced arthritis through regulating the balance between Th17 and regulatory T cells in gut-associated lymphoid tissues" [Toxicology and Applied Pharmacology, 282/1 (2015) 90-99].
Tong B, Dou Y, Wang T, Yu J, Wu X, Lu Q, Chou G, Wang Z, Kong L, Dai Y, Xia Y. Tong B, et al. Among authors: wu x. Toxicol Appl Pharmacol. 2024 May;486:116948. doi: 10.1016/j.taap.2024.116948. Epub 2024 Apr 27. Toxicol Appl Pharmacol. 2024. PMID: 38685279 No abstract available.
Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial.
Ruan DY, Liu FR, Wei XL, Luo SX, Zhuang ZX, Wang ZN, Liu FN, Zhang YQ, Yang JW, Chen ZD, Wang YS, Wang JY, Liang XH, Wu XJ, Zheng YL, Liu J, Shi X, Kumar R, Liu W, Chen B, Zhang DS, Xu RH. Ruan DY, et al. Among authors: wu xj. Lancet Oncol. 2025 Jan 6:S1470-2045(24)00636-3. doi: 10.1016/S1470-2045(24)00636-3. Online ahead of print. Lancet Oncol. 2025. PMID: 39788133
59,145 results
You have reached the last available page of results. Please see the User Guide for more information.